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We have recently generated a novel medulloblastoma (MB) mouse model with activation
of the Shh pathway and lacking the MB suppressor Tis21 (Patched1+/−/Tis21KO). Its
main phenotype is a defect of migration of the cerebellar granule precursor cells (GCPs).
By genomic analysis of GCPs in vivo, we identified as drug target and major responsible
of this defect the down-regulation of the promigratory chemokine Cxcl3. Consequently,
the GCPs remain longer in the cerebellum proliferative area, and the MB frequency
is enhanced. Here, we further analyzed the genes deregulated in a Tis21-dependent
manner (Patched1+/−/Tis21 wild-type vs. Ptch1+/−/Tis21 knockout), among which
are a number of down-regulated tumor inhibitors and up-regulated tumor facilitators,
focusing on pathways potentially involved in the tumorigenesis and on putative new drug
targets. The data analysis using bioinformatic tools revealed: (i) a link between the Shh
signaling and the Tis21-dependent impairment of the GCPs migration, through a Shh-
dependent deregulation of the clathrin-mediated chemotaxis operating in the primary
cilium through the Cxcl3-Cxcr2 axis; (ii) a possible lineage shift of Shh-type GCPs toward
retinal precursor phenotype, i.e., the neural cell type involved in group 3 MB; (iii) the
identification of a subset of putative drug targets for MB, involved, among the others, in
the regulation of Hippo signaling and centrosome assembly. Finally, our findings define
also the role of Tis21 in the regulation of gene expression, through epigenetic and RNA
processing mechanisms, influencing the fate of the GCPs.
Keywords: medulloblastomamodel, cerebellar precursor cell, drug target, Sonic Hedgehog, primary cilium, neural
migration, retina, chemokines
INTRODUCTION
About 30% of medulloblastomas (MBs), the pediatric tumor of the cerebellum, originates from the
granule neuron precursor cells (GCPs) located in the external granular layer (EGL), at the surface
of the developing cerebellum, in consequence of hyperactivation of the Sonic Hedgehog (Shh)
pathway (Kadin et al., 1970; Schüller et al., 2008; Yang et al., 2008; Gibson et al., 2010; Northcott
et al., 2012). Other MB subtypes may originate from neural precursors of the cerebellar embryonic
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anlage, different from GCPs and dependent on Wnt signaling,
or from GCPs with activation of different pathways (group 3),
or also from neural precursors of unknown origin (group 4;
Northcott et al., 2012). GCPs intensely proliferate postnatally
in the EGL, before exiting the cell cycle and migrating inward
to form the mature internal granular layer (IGL; Hatten, 1999).
GCPs in the EGL are forced to divide by the proliferative
molecule Shh, secreted by Purkinje neurons (Dahmane and Ruiz
i Altaba, 1999; Wallace, 1999; Wechsler-Reya and Scott, 1999).
It is believed that the prolonged mitotic activity of the GCPs,
consequent to hyperactivation of the Shh pathway, makes them
potential targets of transforming insults (Wang and Zoghbi,
2001).
We have previously shown that mice lacking one allele of
Ptch1, which develop MB with low frequency as result of the
activation of the Shh pathway (Hahn et al., 1998), when crossed
with mice knockout for the MB suppressor Tis21 develop MB
with very high frequency (Farioli-Vecchioli et al., 2012a,b). We
identified as responsible for this effect a defect of migration of the
GCPs that, remaining for a longer period in the EGL under the
proliferative influence of Shh, developed tumor more frequently.
Whole-genome analyses of expression and function indicated
that the key molecule responsible for the lack of migration of
GCPs is the chemokine Cxcl3 (Farioli-Vecchioli et al., 2012a).
Together with Cxcl3, we identified other 187 gene sequences,
163 of which have a functional product, whose expression in
double mutant Ptch1 heterozygous/Tis21 knockout mice was
modified, relative to Ptch1 heterozygous mice in Tis21 wild-
type background (single mutants; Farioli-Vecchioli et al., 2012a).
The set of genes whose expression significantly differs in the
comparison Ptch1+/−/Tis21 wild-type vs. Ptch1+/−/Tis21KO will
be hereafter defined as Set A (Figure 1).
Here, we aimed to expand the functional investigation of the
previous whole-genome analysis of gene expression alterations
occurring at the onset of tumorigenesis in the GCPs, in order to
further examine the set of genes whose expression is modified in
Ptch1 heterozygous/Tis21 knockout double mutant mice relative
to Ptch1 heterozygous/Tis21 wild-type mice (Set A).
Given that Tis21 mutation has a strong tumorigenic effect
in Ptch1 heterozygous background, with a high increase of MB
frequency, we assumed that the transcriptional changes occurring
in the Set A of 163 genes after Tis21 ablation in Ptch1 background
were at the origin of the increased tumorigenicity observed.
These genes, referred to as Tis21-dependent—given that their
expression is by definition modified by the ablation of Tis21 in
Ptch1 heterozygous background—will be divided in up-regulated
and down-regulated, relative to Ptch1 heterozygous/Tis21 wild-
type mice. It is worth noting that among the genes in Set A
whose expression is down-regulated abound those with tumor-
inhibitory activity (e.g., Pag1, PadI4, Lats2, and Cxcl3), while
among the up-regulated genes are present tumor facilitators (e.g.,
Rab18, Dek).
Phenotypically, our genomic data refer to GCPs at a very early
pre-neoplastic stage, having been isolated from 7 day-old mice,
i.e., when the neoplastic lesions have not yet emerged.
The data analyzed interestingly lead to: (i) a link between
the Shh signaling and the impairment of the GCPs migration,
through a Shh-dependent deregulation of the receptor-mediated
endocytosis pathway; (ii) a possible lineage shift of Shh-type
GCPs toward retinal precursor phenotype/toward the neural cell
type involved in group 3 MB; (iii) the identification of a subset
of putative drug targets for MB involved in the regulation of
cell cycle, Pdgf, Rapamycin target protein 1 and Hippo signaling
pathways. Finally, our findings indicate a role of Tis21 in the




Genome-wide expression study design and experimental
procedures, of GCPs isolated from the EGL of P7, mice were
previously performed with Whole Mouse Genome Microarrays
(Agilent Technologies), as described in Farioli-Vecchioli et al.
(2012a). GCPs were isolated from Ptch1 heterozygous/Tis21
knockout double mutant and Ptch1 heterozygous/Tis21 wild-
type mice of either sex (Farioli-Vecchioli et al., 2012a). In order
to extract the mRNA from GCPs for microarray analysis, for
each of the four genotypes were used 4 replicates of GCPs
isolated from 3-4 mice each, for a total of about 64 mice
(Farioli-Vecchioli et al., 2012a). The experiments and all animal
procedures were completed in accordance with the current
European (directive 2010/63/EU) Ethical Committee guidelines
and approved by the Ethical Committee of the Italian Ministry of
Health (authorized protocol number 14/2009 dated 14/12/2009,
expiry date 14/12/2012, according to Law Decree 116/92).
Experiments performed after 14/12/2012 are authorized by the
Ethical Committee of the Italian Ministry of Health by protocols
307/2013-B and 193/2015-PR expiring 30/03/2020.
Functional Data Analysis
Raw data from microarrays experiments were processed and
analyzed using GeneSpringGX 12.5 (Agilent Technologies), as
already described (Farioli-Vecchioli et al., 2012a). Pathway
enrichment analysis of Set B and Set D genes was performed
with MetaCoreTM by Thomson Reuters (Ekins et al., 2007).
Pathways with corrected enrichment p-value p < 0.05 were
considered significant. MetaCoreTM integrated software for
functional analysis and its manually curated database have also
been used for functional annotation of Tis21-dependent Set A
genes, together with DAVID Bioinformatics Resources version
6.7 public database by the National Center for Biotechnology
Information (NIH) (Huang da et al., 2009a,b), Mouse Genome
Database (MGD) by The Jackson Laboratory, Bar Harbor, Maine
(Blake et al., 2014), Cerebellar Development Transcriptome
Data Base (CDT-DB) by NIJC, RIKEN-BSI, Japan (Sato et al.,
2008) and Universal Protein Resource (UniProt) by the UniProt
Consortium (Consortium, 2014).
Drug Target Analysis
To identify potential drug targets among the Set A differentially
expressed genes, we have used the drug target selection tool
via gene list analysis by MetaCoreTM (Thomson Reuters) (Ekins
et al., 2007) and Thomson Reuters Cortellis Drug Viewer tool
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FIGURE 1 | A Venn diagram showing four genotype pairwise comparisons and the intersection of their differentially expressed gene/sequences set
A–D. Set A corresponds to the pairwise comparison Ptch1+/−/Tis21KO vs. Ptch1+/−/Tis21+/+; Set B refers to Ptch1+/−/Tis21+/+ vs. wild type; Set C concerns
Ptch1+/−/Tis21KO vs. Ptch1+/+/Tis21KO; Set D represents the double-knockout contribution in background wild type.
(also available on MetaCoreTM platform) via pathway analysis.
The search has been performed among human primary/direct
(Table 3) and secondary/indirect (Table 4) drug targets (see
OrthoDB Kriventseva et al., 2015, for the comparison between
human and mouse orthologs). The drugs have been taken into
account for their targets and not for their use, so not only
anti-neoplastic agents are listed in Tables 3–6. CortellisTM drugs
results were compared with records contained in public databases
such as DrugBank version 4.2 (Knox et al., 2011; Law et al.,
2014), PubChem Compound by NIH (Bolton et al., 2010) and
Naturally Occurring Plant based Anticancerous Compound-
Activity-Target (Mangal et al., 2013). Finally, to further annotate
Set A list genes with respect to known drug-gene interactions and
potential druggability, in both mouse and human, we have used
the search tools on The Drug Gene Interaction Database (DGIdb)
(Griffith et al., 2013) via gene list (Figure 3, Tables 4, 5).
RESULTS AND DISCUSSION
Whole-Genome Expression Changes
Underlying Tis21-Dependent Activity in
GCPs during Cerebellum Development
By using oligonucleotide microarrays, we monitored the
transcriptomic profiles belonging to GCPs isolated at postnatal
day 7 (P7), i.e., cells under the proliferative and tumorigenic
influence of Shh deregulated signaling in EGL. When expression
profiles of genes from either Ptch1 heterozygous GCPs in
Tis21 wild-type background (Ptch1+/−/Tis21+/+) or double
mutant (Ptch1+/−/Tis21KO) GCPs were compared with
the control wild-type (Ptch1+/+/Tis21+/+), a consistent
subset of genes showed a significant change in expression
level, i.e., 2599 in Ptch1+/−/Tis21+/+ (Figure 1 Set B) and
3525 in Ptch1+/−/Tis21KO (Figure 1 Set D). Instead, the
contribution of Ptch1+/− in Tis21 Knockout background was
exemplified by 5381 differentially expressed genes (Figure 1 Set
C; Ptch1+/−/Tis21KO vs. Ptch1+/+/Tis21KO).
Here we analyze and discuss mainly those genes that
were differentially expressed in the pairwise comparison
Ptch1+/−/Tis21KO vs. Ptch1+/−/Tis21+/+ (Set A; Figure 1;
Supplementary Table 1), to identify the contribution by Tis21
in Ptch1 heterozygous background. These genes are critical as
they underlie the great increase of MB frequency observed in
Ptch1 heterozygous mice ablated of Tis21 (Ptch1+/−/Tis21KO),
relative to Ptch1 heterozygous mice in a wild-type background
(Ptch1+/−/Tis21+/+). Tis21-dependent mechanisms underlying
the onset of Shh-type MB in GCPs during pre-neoplastic
development involve a set of 188 sequences (Figure 1 Set A).
Among them, about 170 encode for proteins with a known
function. In particular, 13 genes belonging to a subset of set A
(Figure 1) showed a change of expression that was influenced
exclusively by the ablation of Tis21: Tigar, Dsc2, Padi4, Serbp1,
Lnx1, Pag1, Olfr670, Mcemp1, Cldn22, Slc25a15, Pth, Pdgfd and
Cxcl3.
The validation of some of these genes has already been
performed by quantitative real-time PCR (Farioli-Vecchioli et al.,
2012a).
Functional Analysis of Ptch1
heterozygous/Tis21-Null Mouse Model
Deregulated Genes
Deregulated genes in our pre-neoplastic model mainly belong to
developmental pathways that affect different cellular processes
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such as cell cycle regulation, proliferation, cell adhesion,
cytoskeleton remodeling, apoptosis, survival and differentiation
(Table 1). In particular, genes belonging to developmental
signaling cascades, differentially expressed in our Shh-
deregulated model, depend on the Ptch1 mutation contribution
as inferred by set B vs. set D data analysis (Figure 2). As well
known in the literature, in fact, developmental cascades, when
deregulated, acquire oncogenic effect. Neuronal development
and tumorigenesis rely on cell communication via identical
signaling pathways, resulting in a complex signaling network
that creates a breeding ground for tumor-initiating events (Peifer
and Polakis, 2000; Schwartz and Ginsberg, 2002; Clark et al.,
2007; Katoh, 2007; Neth et al., 2007; Guo and Wang, 2009;
Rodini et al., 2010; Mimeault and Batra, 2011; Roussel and
Hatten, 2011; Akhurst and Hata, 2012; Manoranjan et al., 2012).
At the same time, Tis21 ablation is responsible for the delayed
migration of pre-neoplastic precursors outside the EGL, which
corresponds to a delayed cell differentiation and represents
the key step for MB Shh-type formation. In fact, where GCPs
proliferate for a prolonged period in EGL, they became the
target of neoplastic transforming insults (Farioli-Vecchioli et al.,
2012a,b).
Moreover, we have noticed evidence for the involvement of the
primary cilium in our GCPs pre-neoplastic model, mainly in Set
B but also in Set A data (Figure 3), and also evidence of Smo-
dependent non-canonical Shh pathways. A link between Shh
signaling at primary cilium and clathrin-mediated endocytotic
trafficking/cytoskeletal remodeling will also be discussed.
Another observation is related to the mitogen role of Shh
signaling, not only in the developing cerebellum but also in
the neuronal tube and overall in the retinal cell specification.
In fact, a large number of deregulated genes in our Set A are
also involved in the delayed differentiation of retinal cell types.
Notably, it has been previously shown a parallelism between MB
and retinal development; in fact, the analysis of cell populations
in MB-derived from GCPs (particularly the group 3) suggests the
TABLE 1 | The most informative deregulated genes belonging to the Set A and associated with the influence of Tis21 gene in background Ptch1
heterozygous (GCPs at P7).
Process Text type Down-regulated in Set A Up-regulated in Set A Enrichment
probability
Cell Cycle NS Wtap, Sik2, Rab11fip4, Lats2, Zc3h12d,
Sema4b, Tigar
Pa2g4, Srpk2, Eif3a, Eif3c, Eif2c1, Taok2,
Mphosph10, Rrp1, Ipo7, Taf7, Cdc27, Ckap5
0.000004
Cytoskeleton NS Cdc42bpb, Sik2 Ehbp1, Akap2, Rab18, Ckap5, Emd 1
Protein Ubiquitination NS Lnx1, Nfx1 Ube2o, Cdc27, Smurf2, Usp36 0.03787
Cell Proliferation NS Pag1, Gcnt3, Sema4b Agtr2, Eif2c1, Gtpbp4, Rps12, Slc6a6 0.69694
Apoptotic Process NS Tigar, Ppp1r13l, Serpina3g Vdac1, Ripk3, Rbm5, Isoc2b, Sltm, Cxcl12 0.32304
Cell Adhesion NS Col4a6, Col23a1, Dsc2, Cldn22, Egflam – 0.39940
Cell differentiation NS Zfhx2os, Dazl Deptor, Foxf2, Lhx5 0.45675
Primary Cilium MT Ccdc157, Ccdc171, Rab11fip2, Rab11fip4,
Cxcl3
Syne2, Rgs5 0.00001
Vescicle-mediated transport MT Rab11fip4, Rab11fip2, Cxcl3 Ehbp1, Zfyve20, Cxcl12, Sgsm2, Ckap5, Vps35,
Rab18, Smurf2
0.00574
Retinal Development MT H19, Col4a6, Rab11fip4, Bsn, Efna4, Egflam Vdac1, Taf7, Emd, 9130401M01Rik, Taok2,
Hist3h2ba, Tomm22, Vps35, Slc6a6, Pafah1b1,
Akap2, Raly, Rps12, Nlk, Pa2g4, Srpk2, Dgkq, Cdc27,
Syne2, Ripk3
0.000000
Developmental Process SD Gpr82, Smg1, H19, Mettl14, Fat4, Sema4b,
Lats2
Rgs5, Sgsm2, Emd, Rab18, Vps35, Nlk, Gigyf2,
Kctd5, Ankrd11, Cxcl12, Pdgfd
0.00007
Cell Migration MT Cxcl3, Jmy, Efna4, Timp1, Frk, Prrx1,
Rab11Fip2
Cxcl12, Pdgfd, Pafah1b1 0.00008
Epigenetic Modulation SD Hist2h2bb, Cbx3, Padi4 Hist3h2ba, Ankrd11, Ankrd24, Ankrd26, Brwd1, Dek,
Anp32a, Taf7, Pa2g4, Emd, Ipo7
0.000000
RNA Processing SD Wtap, Mettl14 Rbm5, Raly, Srpk2, Ddx23, Dek, Htatsf1 0.00312
Nonsense-mediated mRNA
decay
SD Smg1, Upf3b – 0.00755
Ribonucleoprotein complex
biogenesis and assembly
SD – Eif3a, Eif3c, Eif2c1, Rmnd1, Rrp1, Gtpbp4, Rps12,
Mphosph10, Ipo7
0.00003
Shh-type MB genes MT Gli1* Pdgfd 0.0164
Group 3 MB genes MT Nlk, Ppp2r2b*, Raf1* 0.0161
The genes are clustered in pathways of involvement, according to the functional analysis methods following described. Many genes overlap different clusters. We divide the genes into
two categories: down-regulated and up-regulated, depending on whether the mutation of Tis21 causes in double mutant mice an increase or decrease of expression, respectively,
relative to Ptch1 heterozygous/Tis21 wild-type mice. *Genes whose levels are changed in Set A although not significantly accordingly to the statistical analysis performed. The functional
classes involved in our study have been discussed in the main text (MT), in the Supplementary Data (SD) or are not shown (NS). The enrichment probability of the deregulated genes in
each functional class has been calculated using the Fisher Exact Text.
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FIGURE 2 | A molecular overview of our Shh-deregulated mouse model, characterized by the genetic disruption of hedgehog signaling resulting from
a heterozygous mutation in the negative regulators Ptch1, whose effects are enhanced by the homozygous deletion of the Tis21 tumor suppressor
gene. The figure shows the proteins mainly involved in neural developmental pathways, encoded by the differentially expressed genes of set B and set D and shown
in their subcellular compartments. Each differentially expressed pathway object is labeled with a thermometer that indicates the gene expression changes: downward
thermometers have a blue color and indicate down-regulated expression, whereas upward thermometers have a red color and indicate up-regulated expression. The
thermometer number 1 is related to the pairwise comparison Ptch1+/−/Tis21+/+ vs. wild type Set B, while the thermometer number 2 is related to the pairwise
comparison Ptch1+/−/Tis21−/− vs. wild type Set D. Signaling cross-talks between developmental pathways involved in pre-neoplastic GCPs development are
initiated by different growth factors and cytokines, the most part of which interacts with G-protein coupled receptors. This is supported by a strong up-regulation of
many members of heterotrimeric G-proteins, their target molecules and regulators (data not shown in figure). Among those reported in literature as involved in MB
(Roussel and Hatten, 2011), developmental signaling pathways appear to be up-reregulated in our experimental data, according to the far fewer percentages of
negative signature genes (Chen et al., 2013) and the over-representation of WNT and axonal guidance genes present in human MB Shh-type (Northcott et al., 2011).
Interestingly, a β-Catenin-Gli1 balanced interaction has been recently reported to regulate Shh-driven MB tumor growth in Ptch1 heterozygous mice in vitro (Zinke
et al., 2015), while Sox7, a transcription factor that is known to reduce Wnt/β-Catenin stimulated transcription in a dose-dependent manner (Takash et al., 2001), is
up-regulated in Set B and Tis21 ablation enhances its up-regulation in Set D (data not shown in figure). Furthermore, Smo-dependent non-canonical Shh pathways
(Jenkins, 2009), which have been reported to modulate cytoskeleton-dependent processes and fluctuation of Ca2+ through the plasma membrane in mammalian
neurons (Brennan et al., 2012) and suggested in possible association with MB (Briscoe and Therond, 2013), are put in light here for the first time as related to the MB
Shh-type mouse model. Evidences of a deregulated Slit-Robo pathway, which is implicated in neuronal migration (Wong et al., 2001; Marillat et al., 2004), are present
in our data with the up-regulation of the axon guidance receptor Robo4. The ligand of Robo4, Slit2, has been linked to the inhibition of MB cell invasion
(Werbowetski-Ogilvie et al., 2006). Proteins belonging to the ubiquitin-dependent degradation of GCPs cell cycle regulators [24] have their genes up-regulated in our
model, in particular a number of ubiquitin-conjugating enzymes and some constituents of the SCF (Skip1, Cullin1, F-box)-E3 ubiquitin ligase complex. Among them, a
substrate recognition component of the SCF-type E3 ubiquitin ligase, the F-box protein Fbw7, which has been linked to a premature migration of GCPs in conditional
Fbw7-knockout mice [30]. An up-regulation genes coding for proteins involved in palmitoylation (i.e., HHAT) and transport of Shh (i.e., DISP1) is noticed in in Set D,
where Ptch1 sterol-sensing domain seems to control Smoothened activity through Ptch1 vesicular trafficking [34]. Retinoblastoma-associated protein (Rb), as well as
its downstream effectors E2F3 and E2F5, has its correspondent gene up-regulated in set D, where the deregulation of the Rb/E2F tumor suppressor complex in MB
Shh-driven has been already associated to the E2F1-dependent regulation of lipogenic enzymes in primary cerebellar granule neuron precursors (Bhatia et al., 2011).
Figure 4 below shows the set of symbols whereby network objects and interactions between objects are indicated in this figure.
occurrence of a potential aberrant trans-lineage differentiation
into retinal neuronal precursors (Kool et al., 2008; Hooper et al.,
2014). Here, given the large number of genes comprised in set A
that is deregulated during the retinal cell development, we want
to focus our attention on the timing of exit from the cell cycle,
a crucial step in retinal cell development and differentiation,
Frontiers in Pharmacology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 449
Gentile et al. Tis21-Dependent Medulloblastoma Drug Targets
FIGURE 3 | Drug targets belonging to the Set A discussed in the main text. Each gene product is labeled with a thermometer indicating the gene expression
changes: downward thermometers have a blue color showing down-regulated expression, whereas upward thermometers have a red color showing up-regulated
expression. The most part of the figure objects are deregulated also in other two pair comparisons. For this reason, the thermometer number 1 is related to the
pairwise comparison Ptch1+/−/Tis21+/+ vs. wild type or Set B, the thermometer number 2 is related to the pairwise comparison Ptch1+/−/Tis21−/− vs. wild type
or Set D, while the thermometer number 3 is related to the pairwise comparison Ptch1+/−/Tis21KO vs. Ptch1+/−/Tis21+/+ or Set A. See Figure 4 for the set of
symbols, objects and interactions between objects indicated in this figure.
which is under the influence of Shh signaling, as it occurs in the
development of MB Shh-type (Dyer, 2004). These considerations
will be taken into account for a parallel comparison with our
model data.
Finally, a fine regulation at RNA processing, ribosomes and
vesicle trafficking level but also an epigenetic modulation were
noticed in set A deregulated genes (Table 1). In the following
paragraphs, we will discuss the most informative deregulated
coding genes belonging to the set A according to their functional
clusters (Figure 3 and Table 1), the most of which overlap
different clusters. Among them, there is a large number of already
known genes as oncogenes and tumor suppressors. In doing this,
we have also taken into account the genes which are deregulated
in consequence of the Ptch1 heterozygous.
Primary Cilium Roles in GPCs Proliferation and
Differentiation
Primary cilia are sensory non-motile microtubule-based
organelles (Lee and Gleeson, 2010) protruding from the surface
of GCPs in the EGL at early post-natal stages (Del Cerro and
Snider, 1972), whose requirement for Shh-induced expansion
and cerebellar development has been proved using mutants
of genes involved in the ciliary formation and maintenance
(Chizhikov et al., 2007; Spassky et al., 2008). Among them,
the genetic ablation of primary cilia by removing Kif3a (which
encodes the microtubule plus end-directed kinesin motor 3A
protein), blocked MB formation driven by a constitutively
active Smoothened protein (Han et al., 2009). Therefore,
Kif3a down-regulation blocks MB Shh-type formation in
a primary cilia-dependent manner; moreover, its activity
is not required for GCPs differentiation (Chizhikov et al.,
2007). In our model, we observe that Kif3a is up-regulated
in Ptch1 heterozygous mice, irrespective of the presence
or absence of Tis21, which is therefore not involved in the
Kif3a-dependent phenotype (Figure 2). This is consistent
with the finding that Kif3a is required for the proliferation of
the GCPs (Chizhikov et al., 2007) and with our observation
that Tis21 in cerebellum regulates the migration of the GCPs
but not their proliferation, while the opposite occurs for
Ptch1.
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Nevertheless, in our model, several genes encoding for
the coiled-coil domain containing proteins are deregulated in
Set A, and thus are dependent on Tis21, i.e., Ccdc157 and
Ccdc171 (Table 1). One-fourth of the deregulated genes in Set
A corresponds to coiled-coils proteins (data not shown), whose
highly versatile protein folding motif is related to different
biological processes, from subcellular infrastructure maintenance
to trafficking control (Burkhard et al., 2001; Rose et al., 2005)
and cilia-related (McClintock et al., 2008; Munro, 2011). A
coiled-coil containing protein is also Rab11 family-interacting
protein 4 encoded by Rab11fip4 (Muto et al., 2006, 2007),
whose role in our model will be discussed more in detail
in other paragraphs together with the functional product of
Rab11fip2, and their wide implication in Shh signaling at
primary cilium as a protein involved inmicrotubule-based vesicle
trafficking. Another protein, Nesprin-2 encoded by Syne2, is
known to mediate centrosomemigration and is essential for early
ciliogenesis and formation of the primary cilia by the interaction
with the coiled-coil domain of Meckelin protein (Dawe et al.,
2009). Notably, Ccdc157, Ccdc171, Rab11fip2, and Rab11fip4
are significantly down-regulated in Set A, while Syne2 is up-
regulated. Also a novel repressor of hedgehog signaling, whose
gene Rgs5 is up-regulated in set A, has been proven to be present
with Smo in primary cilia (Mahoney et al., 2013). This would
suggest that Tis21-dependent tumorigenesis in a (proliferation-
independent) way involves ciliogenesis. This latter may be also
enhanced by Syne2 after Tis21 ablation.
Evidences of direct involvement of Shh signaling on the
increase of Ca2+ levels (Ca2+ spikes) have been shown at the
primary cilium of chicken embryonic spinal neurons. In this
system has been observed that Shh (a recombinant N-terminal
molecule) may recruit second messengers (i.e., calcium—Ca2+—
and inositol triphosphate) by a non-canonical pathway, through
the activation of the Smoothened protein, which translocates
to the cilium and becomes activated by phosphorylation at
its C-terminal from a G-protein-coupled receptor kinase 2
(Riobo et al., 2006; Belgacem and Borodinsky, 2011; Brennan
et al., 2012). Belgacem and Borodinsky (2011) proposed a
model in which the primary cilium acts as a subcellular
compartment for Shh signaling allowing the spatiotemporal
integration of the second messengers through a Smoothened-
dependent recruitment of Gi proteins and Phospholipase C that
in turn increases inositol triphosphate levels. The opening of
Inositol triphosphate receptors-operated stores and the following
activation of Transient receptor potential cation channel 1
(Trpc1) results in an increased Ca2+ spike activity. This model
could fit with our data (Figure 3) in which Plc-gamma2, Ip3r3,
Trpc1, Trpc2, and Trpc3 are up-regulated in Ptch1 heterozygous
mice (but independently from Tis21). Notably, this is the first
time that such regulation is observed directly in a mouse model
of Shh-typeMB, as it had been previously only suggested (Briscoe
and Therond, 2013). Furthermore, the authors suggested that the
Smoothened-dependent Ca2+ spike activity is necessary for Shh-
induced differentiation of spinal postmitotic neuron. Moreover,
the role of second messenger signaling in the regulation of
cerebellar granule cell migration has been studied in different
mousemodels (Komuro et al., 2015), which highlighted the direct
evidence of the role of Ca2+ signaling in granule cell turning and
modulation of their migration rate. The revision of these studies,
performed by Komuro et al. (2015), suggested the role of Ca2+
as potential therapeutic target for some deficits in granule cell
migration since its downstream effectors control the assembly
and disassembly of cytoskeletal elements.
In the last years, the discovery of the role of the primary
cilium in Shh signaling captured the attention of the scientific
community, leading to test a large number of molecules that
modulate SMO cilial translocation acting on different therapeutic
potential targets in different types of cancer among which
MB (Amakye et al., 2013). Loss of cilia in cancer has been
suggested to be responsible for an insensitivity of cancer
cells to environmental repressive signals, based in part on
derangement of cell cycle checkpoints governed by cilia and
centrosomes (Plotnikova et al., 2008). The importance of the role
of cilia in Shh-driven medulloblastoma allografts derived from
Ptch1+/−P53−/− mice has been shown using a Shh antagonist,
i.e., arsenic trioxide (a therapeutic agent for acute promyelocytic
leukemia), which inhibits the growth of tumor through the
prevention of Shh ciliary accumulation and the reduction of the
stability of the Gli2 transcriptional effector (Kim et al., 2010).
Receptor-Mediated Endocytosis Mechanisms,
Microtubule-Based Vesicle Recycling and
Intracellular Membrane Trafficking
Other genes deregulated in Set A are involved in endocytic
trafficking clathrin-dependent (Figure 5), and a certain number
is related to cytoskeletal remodeling and primary cilium that
could be very interesting for their implications for target therapy.
The clathrin-dependent endocytic mechanism is a receptor-
mediated endocytosis type, which involves clathrin-coated
vesicles, early endosomes, microtubule-based vesicle trafficking,
lysosomes and recycling transport vesicles in its pathway (Le Roy
and Wrana, 2005). Evidences of a deregulated clathrin-mediated
endocytosis pattern have been reported for MB group 4 during
early human neurogenesis (Hooper et al., 2014), and detected
in our Set B (data not shown) as well as in Set A, where a large
number of deregulated genes belongs to this signaling: Rab11fip4
(Horgan and McCaffrey, 2009), Ehbp1 (Guilherme et al., 2004),
Rab11fip2 (Fan et al., 2004), Zfyve20 (de Renzis et al., 2002;
Naslavsky et al., 2004), Cxcl12 (Fan et al., 2004; Teicher and
Fricker, 2010; Zhu et al., 2012), Sgsm2 (Yang et al., 2007), Ckap5
(Foraker et al., 2012), Vps35 (Foraker et al., 2012), and Rab18
(Foraker et al., 2012).
Rab11fip4 is known to interact with Rab11 (a Rab GTPase
involved in the regulation of intracellular membrane trafficking),
which in turn interacts with Rab-coupling protein, a protein
involved in the formation of lamellipodia, which facilitates
invasive cancer cell migration (Kelly et al., 2012). Ehbp1
gene product is involved in actin reorganization coupled to
endocytosis clathrin-mediated (Guilherme et al., 2004). Zfyve20
is known to regulate structure, sorting, endocytic/recycling
pathway of the early endosomal compartment by the interaction
with Rab4 and Rab5 (de Renzis et al., 2002; Naslavsky et al.,
2004). Vps35, among other genes involved in intracellular
membrane trafficking, is deregulated in Set A. It encodes for
Frontiers in Pharmacology | www.frontiersin.org 7 November 2016 | Volume 7 | Article 449
Gentile et al. Tis21-Dependent Medulloblastoma Drug Targets
FIGURE 4 | The figure shows symbols, objects and interactions between objects indicated in Figures 2, 3.
FIGURE 5 | Drug targets percentage per functional class of the Set A deregulated genes. The drug targets identified in Set A are showed as percentage with
respect to the functional classes to which they belong.
the vacuolar protein sorting-associated protein 35, a component
of the trimeric cargo-selective retromer complex, required for
the efficient endosome-to-Golgi recycling of many membrane
proteins among which Wntless. It is also known to regulate
endosomal tubule dynamics (Harbour et al., 2010; Berwick and
Harvey, 2014). The oncogene Rab18 is required for normal ER
structure and the regulation of endocytic traffic (Lütcke et al.,
1994; Gerondopoulos et al., 2014). This RabGTPasi is also known
as a MB antigen (Behrends et al., 2003). Interestingly, Rab18
has been localized at lipid droplets (LDs) level (Martin et al.,
2005), and its overexpression causes close apposition of LDs to
membrane cisternae connected to the rough ER (LD-associated
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membrane or LAM) (Ozeki et al., 2005). Indeed, de novo lipid
synthesis has been found in certain highly proliferative and
aggressive tumors such as MB Shh-type, suggesting that the Shh-
E2F1-FASN axis regulating de novo lipid synthesis in cancers
could be used as therapeutic target in hedgehog-dependent
tumors (Bhatia et al., 2011). Remarkably, Rab11fip2 encodes for
a Rab11 family-interacting protein 2, which directly interacts
with the actin-based myosin Vb motor protein regulating Cxcr2
recycling and receptor-mediated chemotaxis; hence, Rab11fip2
links Rab11 to molecular motor proteins and cell migration
(Jones et al., 2006; Horgan and McCaffrey, 2009). Moreover, the
passage of the internalized Cxcr2 through the Rab11-recycling
system appears to have a key role in the physiological response
to a chemokine that follows to the formation of clathrin-coated
vesicles; in fact, Rab11 family-interacting protein 2 can form a
complex with AP-2 that is a major clathrin adaptor complex in
cells (Cullis et al., 2002; Fan et al., 2004; Le Roy and Wrana,
2005). Furthermore, the Rab11 involvement into the regulation
of vesicular trafficking during primary ciliogenesis has been
already put in light (Knödler et al., 2010; Hsiao et al., 2012).
A consequence of the above findings, indicating an interaction
between Cxcr2 and the clathrin pathway, is that, since Cxcl3
binds the Cxcr2 receptor (Zlotnik et al., 2006), we can infer
that this chemokine receptor-mediated chemotaxis mechanism
is clathrin-dependent and linked through Rab11fip2 to the
primary cilium, in which the Shh signaling takes part. Other
evidence of an involvement of Rab11fips and Shh signaling
derives from Rab11fip4 (see the retina development section).
This protein seems to be involved in the regulation of the
membrane trafficking system through interaction with other
small GTPases, among which could be Ras-related protein Rab-
23, and in the negative regulation of Shh signaling at the primary
cilium (Muto et al., 2007; Hsiao et al., 2012).
All this points to an important link between Shh signaling,
operating through the primary cilium, and GCPs impaired cell
migration, through a clathrin-Cxcl3-Cxcr2-mediated chemotaxis
and microtubule-based endocytic vesicle recycling trafficking.
Furthermore, the findings of a study about the role of
endosomes around mother centriole appendages, and their
Rab11-dependent recycling activity that requires centrosome-
associated endosome proteins (Hehnly et al., 2012), seem to be
in line with our data (see drug target section). Interestingly,
they showed that (i) the appendages of the mother centriole and
recycling endosomes are in intimate contact, as first evidence for
a novel centrosome-anchored molecular pathway and regulation
of endosome recycling; (ii) there is a structural association
between the endosome and the centrosome with new and
unexpected implications for recycling endosome functions, such
us that one related to cilia formation; (iii) it is also possible that
Rab11, and other endosome-associated molecules bound to the
centrosome, may play dual roles in endosome and centrosome
function (Hehnly et al., 2012).
Retinal Development
In mice, retinal development occurs between E11.5 and P8, as
uncommitted neuroblasts leave the cell cycle and commit to
retinal cell fates (Mu et al., 2001). Thanks to mice models, it is
known that aberrant proliferation during the development of the
neural tube, of cerebellum and retina, leads to embryonal and
early postnatal tumors (Dyer, 2004). The potent mitogen Shh
positively controls the proliferation of their neuronal precursor
cells (Martí and Bovolenta, 2002). In particular, Shh signaling
plays a pivotal role in regulating the proliferation of retinal
progenitor cells (RPCs) and the differentiation of retinal ganglion
cells (RGCs) during vertebrate retinal development, acting in
a cell-specific manner; namely, in mouse Shh is required as
positive regulator of RPCs proliferation and as negative regulator
of RGCs production, by inhibiting cell-cycle exit (Wang et al.,
2005; Wallace, 2008).
A further molecular target which may be responsible for
the regulation of retinal cell proliferation and hence for cancer
cell proliferation was suggested to be Rb; in fact, the levels
of Rb protein appear critical for the development of retinal
tumors (Sicinski et al., 1995). The rationale for this is that
Rb, when active, inhibits the cycle at the G1 checkpoint,
prior to cell differentiation, whereas its inactivation, exerted by
phosphorylation from cyclinD1/CDK4, is known to start the
cell cycle progression. Thus, high levels of Rb may be more
difficult to inactivate and vice-versa, thus critically linking the
Rb-dependent developmental regulation of proliferation during
neurogenesis to cancer cell proliferation for certain types of
tissues (Sicinski et al., 1995). Indeed, in our model we observe
that in GCPs heterozygous for Ptch1 (set B: Ptch1+/−/Tis21+/+
vs. Ptch1+/+/Tis21+/+) cyclin D1 expression does not change
while Rb does increase. This suggests that in Shh-driven
neoplastic GCPs the increase of Rb protein is compensatory.
In the case of MB, a parallel between developmental
neurobiology and oncology was suggested for the proliferating
progenitor cells of the retina and cerebellar granule neurons,
where the failure to exit the cell cycle leads to aberrant cell
proliferation during development in mice (Romer and Curran,
2004). Notably, MB-types Cluster D and E (also referred to as
groups 4 and 3, respectively) have been found to be marked by a
deregulated expression of retinal photoreceptor genes suggesting
a distinct origin (i.e., non-cerebellar) from stem cells during the
embryonic development, with respect to MB Shh-type in human
(Kool et al., 2008).
In this context, concerning the contribution of Tis21 deletion
to the MB development, in Set A we noticed a great number
of deregulated genes that have been previously described as
involved in retinal development. This comparison could be useful
to suggest some common mechanisms related to the progenitor
cells cell-cycle exit failure. A consistent subset of Set A genes
has been previously described as being involved in cellular
expression patterns of mouse early retinal development; these
gene were previously recognized by analyzing the outer retinal
neuroblastic layer, which in early developmental stages consists
almost entirely of mitotic progenitor cells: Vdac1, Taf7, Emd,
9130401M01Rik,Taok2,Hist3h2ba,Tomm22,Vps35,H19, Slc6a6,
Pafah1b1, Akap2, Raly, Rps12, Nlk, Pa2g4 and Srpk2 (Blackshaw
et al., 2004). These genes are all up-regulated in Set A except for
H19. Furthermore, a number of other genes that were identified
in other studies as being involved in retinal development, are
down-regulated in set A: Col4a6 (Bai et al., 2009), Rab11fip4
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(Muto et al., 2007), Bsn (Dick et al., 2003), Efna4 (Marcus et al.,
1996; Poliakov et al., 2004; Triplett and Feldheim, 2012), Egflam
(whose product is also known as Pikachurin) (Omori et al., 2012);
conversely, other retinal genes up-regulated in set A are: Dgkq
(Pilz et al., 1995), Cdc27 (Leung et al., 2008), Syne2 (Yu et al.,
2011), Slc6a6 (Vinnakota et al., 1997; Warskulat et al., 2007),
Ripk3 (Trichonas et al., 2010).
The genes listed above belong to different functional clusters,
and some of them will be discussed more in detail in their
paragraph of pertinence. Interestingly, the mouse Rab11fip4,
whose product regulates the Rab GTPases and is predominantly
expressed in the developing neural tissues, among which retina,
acts as regulator of RPCs cell-cycle exit and their subsequent
differentiation (Muto et al., 2007). Rab11fip4 seems to be
involved in the regulation of membrane trafficking system
through interaction with other small GTPases and in the negative
regulation of Shh signaling (Muto et al., 2007). Moreover, the
Syne2 gene product is known to mediate nuclear migration
during mammalian retinal development connecting the nucleus
with dynein/dynactin and kinesin proteins (Yu et al., 2011).
This comparison is in line with the evidence that progenitors
from the developing cerebral cortex, cerebellum and retina
share a common expression program, suggesting a common
evolutionary origin of the different progenitors cells (Livesey
et al., 2004), and implying a possible common differentiation
program. Our data suggest that this developmental process,
possibly at the steps of migration and differentiation, is regulated
by Tis21.
Migration
The migration of the GCPs is known to be induced by
responses to local environmental cues. However, the alterations
of migratory behavior may also depend on intrinsic programs
(Komuro et al., 2013). In our study, we observed in Set A the
differential expression of a great number of genes belonging to
migration, cell adhesion and differentiation mechanisms. Among
the genes implicated in migration seven are down-regulated after
ablation of Tis21 in Shh-activated background, namely, Cxcl3,
Jmy, Efna4, Timp1, Frk, Prrx1, and Rab11fip2, and three are
up-regulated: Cxcl12, Pdgfd, and Pafah1b.
Cxcl3 is a chemokine known to have chemotactic activity
for neutrophils (Wuyts et al., 1999). Chemotaxis but also
angiogenesis seems to be activated by the interaction with its
receptor (Addison et al., 2000; Zlotnik et al., 2006). In our
previously published data, Cxcl3 has been identified as a gene
whose transcription is regulated positively by Tis21 (which
directly associates to the Cxcl3 promoter), suggesting that the
evident role played in vivo by Tis21 as inducer of the migration
of the GCPs out of the EGL might occur through its functional
product; this implies Cxcl3 as a new pharmacological target for
medulloblastoma therapy, also considering that MB lesions were
reduced using this chemokine as treatment (Farioli-Vecchioli
et al., 2012a,b). Recently, the anti-cancer role of this chemokine
has also been recognized for non-small lung cancer, mediated by
the activity of interleukin-27 (Airoldi et al., 2015). Jmy, a junction
mediating and regulatory protein, is known to induce cell
motility by promoting actin assembly and regulating cadherins in
the cytoplasm; in DNA damage conditions it undergoes nuclear
accumulation, where acts as p53-cofactor promoting apoptosis
(Shikama et al., 1999; Coutts et al., 2007; Zuchero et al., 2009).
Together, these findings suggest that the ability of Jmy to regulate
actin and cadherin, by coordinating cell motility with the p53
response, could underlie a common pathway (Coutts et al., 2009).
Furthermore, actin assembly has been found to regulate the
nuclear import of Jmy in response to DNA damage (Zuchero
et al., 2012). Thus, an abnormal activity and/or localization of
Jmy could contribute to tumor invasion, thus making this gene
as a potential tumor therapeutic target (Wang, 2010). In theory,
the down-regulation of Jmy may contribute to enhance the rate
of MB in our mouse model, possibly by controlling the migration
of the GCPs as shown for Cxcl3. Regarding Efna4, this gene
encodes for the EphrinA4 protein that has been linked with the
migration of neuronal cells during development (Poliakov et al.,
2004). A recent study showed that EphrinA4 and the Ephrin
type-B receptor 4 are almost exclusively expressed in Shh MBs,
while other Ephrins are expressed in non–ShhMBs; furthermore,
a strategy of overexpression and silencing, applied specifically
to EphrinB1, showed its ability to control the migration of
MB cell lines (McKinney et al., 2015). Further evidence of the
migration-promoting activity of EphrinA4 has been observed in
human glioma cells, where it acts by accelerating a canonical
FGFR signaling pathway (Fukai et al., 2008). Timp1 protein
product is a metalloproteinase inhibitor known to be involved
in cell adhesion and migration of human neural stem cells
(hNSCs). In fact, through its cell surface receptor CD63, TIMP-
1 activates β1 integrin, FAK (focal adhesion kinase) and the
PI3K (phosphoinositide 3-kinase) signal transduction pathway,
resulting in the migration of hNSCs (Lee et al., 2014). Due to
its chemoattractant properties, TIMP-1 has been identified in
the same study as a therapeutic target for human glioma. The
Frk gene product is a Src kinase known as Tyrosine-protein
kinase FRK, which controls the migration and invasion of human
glioma cells by regulating JNK/c-Jun signaling (Zhou et al.,
2012). Moreover, the Tyrosine-protein kinase FRK acts as a
tumor suppressor in breast cancer by regulating the stability
of PTEN, as the loss of Rak (i.e., Frk) induced tumorigenicity
in immortalized normal mammary epithelial cells (Yim et al.,
2009). In mouse brain, Pten is known to be expressed starting at
approximately postnatal day 0 (Lachyankar et al., 2000) and has
also been correlated with the regulation of neuronal precursor
cell migration (Li et al., 2002). In Set B Pten is up-regulated. The
paired-related homeobox transcription factor 1, which is encoded
by Prrx1, is an epithelial-mesenchymal transition (EMT) inducer
in embryos, where this process is required for the formation of
tissues for which cells originate far from their final destination
(Ocaña et al., 2012). EMT is modified and exploited by cancer
cells for metastatic dissemination and also in cancer cells. In
particular, the loss of Prrx1 has been related to the ability of
cancer cells to acquire tumor-initiating abilities concomitantly
with stem cells properties (Ocaña et al., 2012). Furthermore,
paired-related homeobox transcription factor 1 has been found
to promote tenascin-C–dependent fibroblast migration when its
expression was induced by Focal adhesion kinase 1 (McKean
et al., 2003). Fak is up-regulated in both Set B and Set D. Very
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interesting is the down-regulation of Rab11fip2, whose role in
the endocytic recycling pathway has been linked to cell migration
(Jones et al., 2006) as previously discussed (Section Receptor-
Mediated Endocytosis Mechanisms, Microtubule-Based Vesicle
Recycling and Intracellular Membrane Trafficking).
Among the genes up-regulated in Set A related to migration
there is Cxcl12, which encodes for a deeply studied chemokine
involved in different mechanisms in cancer development and
metastatic invasion (Duda et al., 2011; Hattermann andMentlein,
2013), but also described as involved in the migration of
neuronal cells through both its receptor, C-X-C chemokine
receptor type 4 and Atypical chemokine receptor 3 (Tiveron
and Cremer, 2008; Memi et al., 2013; Yang et al., 2013). Cxcl12
appears to exert an action opposite to Cxcl3, as it promotes
the localization of the GCPs to the EGL by chemoattraction,
being released from meninges (Klein et al., 2001; Zhu et al.,
2002). Thus, the upregulation of Cxcl12, consequent to the
ablation of Tis21, synergizes with the downregulation of Cxcl3 in
preventing the migration of the GCPs from the EGL. Notably,
the chemoattraction of cerebellar granule cells by Cxcl12, whose
receptor C-X-C chemokine receptor type 4 is coupled to a G
protein, is selectively inhibited by the soluble EphB receptor;
this inhibition is blocked by a truncated PDZ-RGS3 lacking the
RGS domain, which activates the G-proteins. Therefore, this
points to the existence of a pathway connecting B ephrins and
Cxcl12 to the regulation of G protein–coupled chemoattraction,
and leads to a model for regulation of migration in cerebellar
development (Lu et al., 2001). In this regard, in our model (Set
A) we have detected not only a down-regulation of Efna4, which
is a cell surface GPI-bound ligand for Eph receptors, but also
the up-regulation of a regulator of heterotrimeric G protein
signaling, i.e., Rgs5. Therefore, in our model the decrease of
Cxcl3 and Efna4 and the increase of Cxcl12 after ablation of
Tis21 in Ptch1 heterozygous mice would synergize in impairing
the migration of GCPs from the EGL. As mentioned above, the
increase of Cxcl12 in the Tis21-null EGL GCPs would prevent
their migration by chemoattraction (Zhu et al., 2002). Moreover,
the PDGFR pathway members have been recently studied in
correlations with MB Shh-driven and MB cell migration, and
an upregulation of PDGFRA (receptor for PDGF-A), PDGF-D
(ligand for PDGFRB) and Cxcl12 has been observed in Shh-
type MB (vs. non Shh MBs). In particular, the activation of the
PDGFR pathway has been shown to activate the Cxcl12 receptor
(i.e., CXCR4, via inhibition of GRK6) and thus cell migration
(Yuan et al., 2013). A relevant caveat of that study is that the
direction of cell migration, relative to the EGL, was not assessed,
having the analysis been conducted only in vitro (Yuan et al.,
2013). In our model, we noticed an up-regulation of Pdgfd and
Cxcl12 genes in Set A, while both Pdgfra and Pdgfrb and also
Cxcl12 are up-regulated in Set B and D (see Figure 3). This
indicates that the heterozygosity of Ptch1 is in itself a condition
inducing the expression of both the Cxcr4 and Pdgfr pathways,
and that the additional ablation of Tis21 further enhances their
activation. Finally, Pafah1b1, up-regulated in Set A, encodes
for Lis1, a microtubule regulator that is required for correct
neuronal migration during development (Hippenmeyer et al.,
2010; Escamez et al., 2012).
Epigenetic Modulation
The transcriptional reprogramming of the epigenetic patterns is
among the causes of tumorigenesis. Nowadays, the epigenetic
regulation of transcription and genome organization in MB Shh-
type pathogenesis is extensively studied (Batora et al., 2014;
Hovestadt et al., 2014; Shi et al., 2014). We have previously
provided a first functional genomic analysis of epigenetically
regulated genes or interacting proteins for our mouse model
Tis21 KO, identified in background either Ptch1 heterozygous or
wild-type (Farioli-Vecchioli et al., 2012b). We also have recently
shown that the Tis21 protein binds to histone deacetylases
(HDAC1/4/9) in GCPs, where they are required for the Tis21-
dependent inhibition of cyclin D1 expression (Micheli et al.,
2016). In the present analysis, a great number of genes
encoding proteins involved in epigenetic regulation appear to be
deregulated in Set A (three down-regulated and 12 up-regulated).
They mostly belong to the category of the Histone modification
rather than to the Chromatin remodeling one (Table 2), which
categories are described in (Arrowsmith et al., 2012; Plass et al.,
2013). Our data are in line with those previously published
highlighting a great number of deregulated or mutated histone
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Histones and enzymes involved in histone modification and chromatin remodeling are
showed in the table. They have been classified in subgroups according to their function
and divided in enzymes that transfer the modification or writers, enzymes that modify
or revert a modification also called editors or erasers and enzymes that mediate the
interactions of proteins or protein complexes with the modification known as readers
(Arrowsmith et al., 2012; Plass et al., 2013).
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modifiers involved in medulloblastoma (Northcott et al., 2012)
and their importance as oncogenes or as tumor suppressors
(Cohen et al., 2011). Furthermore, we highlight also the
deregulation of five Histone modifier Regulators, up-regulated in
Set A, namely: Emd (Berk et al., 2013), Anp32a (Seo et al., 2001;
Fan et al., 2006; Kular et al., 2009), Taf7 (Gegonne et al., 2001,
2013; Kloet et al., 2012), Pag2g4 (Zhang et al., 2003), Ipo7 (Jäkel
et al., 1999; Mühlhäusser et al., 2001). A detailed description of
Set A genes involved in epigenetic modulation is presented in
Supplementary Data, at section “Epigenetic modulation.”
Drug Targets
The increasing recognition of the heterogeneity of molecular
basis underlying cancer allows the identification and
development of molecularly targeted agents and their transfer
to the patients (Rask-Andersen et al., 2011; Saletta et al., 2014).
Here we provide a drug target identification through the genomic
analysis of deregulated MB Shh-type Tis21 knockout-dependent
genes in Set A and, where possible, the identification of
potentially druggable targets (Figure 3, Tables 3–5), performed
using the methods described in the appropriate section. This
analysis has given as a result 20 primary, 31 secondary, 53
druggable targets and 18 gene targets among Set A elements
(Tables 3–6). Their distribution within the functional classes is
showed in Figure 5. and the putative drug targets identified in
SetA, here discussed, are shown in Figure 3.
Among the Set A genes showing a change of expression
influenced exclusively by the ablation of Tis21, there is Pdgfd
that has been discussed in developmental (see Supplemtary
Data) and migration processes as up-regulated gene. Since the
overactivity of PDGF signaling can drive tumorigenesis (Pietras
et al., 2003), and since PDGF-D in particular has been found to
be a potent transforming and angiogenic growth factor (Li et al.,
2003) highly expressed in Shh-typemedulloblastoma (Yuan et al.,
2013), we propose targeting PDGF-D as therapeutic strategy for
medulloblastoma Shh-type, as already studied in other tumors
(Heldin, 2013). Another very interesting drug target could be the
phosphatidylinositol 3-kinase-related kinase Smg1, which here
has been discussed in developmental and nonsense-mediated
decay processes (Supplementary Material) as down-regulated
in Set A (up-regulated in Set D). This protein seems to act
antagonistically with mTOR signaling (González-Estévez et al.,
2012; Du et al., 2014), and this is in functional synergy with
the up-regulation in Set A of Deptor, which negatively regulates
mTOR signaling (Beauchamp and Platanias, 2013). Also Deptor
is one of the druggable target identified in our study. Taken
together, these findings seem to support the importance of mTOR
pathway and its upstream PDGF signaling in the pathogenesis of
medulloblastoma (Mohan et al., 2012).
Other two druggable targets are regulators of cell cycle and
developmental processes: Sik2 and Lats2. The functional product
of Sik2 is localized at the centrosome where its absence leads to a
delay of G1/S transition (Ahmed et al., 2010), while Lats2 encodes
for a centrosomal protein (a serin threonin kinase) whose loss
leads to centrosome fragmentation (Yabuta et al., 2007), also
involved in the regulation of cell cycle G1/S checkpoint, for
its relevance to MB tumorigenesis due to its influence in the
reduction of expression of cyclin-D1 and N-CoR (Park et al.,
2012; Lit et al., 2013). The deregulation of centrosome and
cilia biogenesis have been already described in different human
diseases, in particular, in cancer where a derangement of cell cycle
checkpoints is governed by cilia and centrosomes (Plotnikova
et al., 2008; Nigg and Raff, 2009; Bettencourt-Dias et al., 2011). In
addition to that, Sik2 has been characterized as negative regulator
of Hippo signaling in Drosophila (Wehr et al., 2013). In our
data, other two regulators of Hippo signaling appear to be down-
regulated after ablation of Tis21, Lats2, and Fat4 that we discuss
for their role in the developmental process (Supplementary
Data); both act also as tumor suppressors. This evidence supports
the involvement of Hippo signaling (Roussel and Hatten, 2011)
and centrosome assembly in the pathogenesis of MB.
Another putative drug target belonging to developmental
processes, Rgs5, encodes for an endogenous repressor of Shh
signaling and has been proposed in a recent study as potential
therapeutic target in Hh-mediated diseases. In fact, it was shown
that (i) Rgs5 inhibits the Shh-mediated signaling by activating the
GTP-bound Gαi downstream of Smo and (ii) a physical complex
between Rgs5 with Smo is present in primary cilia (Mahoney
et al., 2013).
The apoptosis is not the only form of cellular death in which
the deregulated genes in Set A are involved. In fact, the Ripk3
functional product, a receptor-interacting protein kinase 3, has
been reported to contribute to both apoptotic and necroptotic
cell death, depending on target availability (Cook et al., 2014;
Vanden Berghe et al., 2014). Since many anti-cancer drugs are
inducers of apoptosis, the induction of RIP3-dependent necrosis
is an attractive strategy to circumvent apoptosis resistance of
cancer cells (Moriwaki and Chan, 2013) that is currently under
investigation (Moriwaki et al., 2015). As Ripk3 expression is
induced after knockout of Tis21 in Shh-activated background,
we may hypothesize that Ripk3 plays in our model a tumor
suppressor role.
The therapeutic advantage of targeting the ubiquitin-
proteasome system has already being successfully investigated
with proteasomal inhibitors in Shh-type MB with in vivo
preclinical studies (Ohshima-Hosoyama et al., 2011) and in
a preliminary study with personalized targeted therapy for
pediatric brain tumors among which MB (Wolff et al., 2012).
However, the targeting of specific enzymes regulating the
ubiquitylation process, e.g., SKP2, a SCF ubiquitin ligase, up-
regulated in Set D (Figure 3), has been recently proposed
as a more specific approach than the previous one (Hede
et al., 2014). Two genes belonging to the ubiquitin-dependent
degradation processes are up-regulated in Set A and have been
identified in this study as putative drug target: Ups36 and
Cdc27. Usp36, encoding for a deubiquitinating enzyme (Quesada
et al., 2004), has been detected as overexpresed in human
ovarian cancer compared to normal ovaries (Li et al., 2008). An
Usp36 homolog, recently detected in Drosophila stem cells, has
been linked to the deubiquitylation of histone H2B and to the
silencing of key differentiation genes, including genes target of
Notch (Buszczak et al., 2009). Whereas the anaphase-promoting
complex component Cdc27 is an E3 ubiquitin ligase able to
control cell cycle progression at the G1 to S transition, and also to
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TABLE 3 | A list containing the direct targets and their drugs obtained using MetaCoreTM (i.e., ATP1A1) and CortellisTM db.
MetaCoreTM/CortellisTM Therapeutic Drug-target direct Interactions
Gene Symbol Target Drug Effect Pubmed
ATP1A1 ATP1A1 Trichlormethiazide intracellular Inhibition
Istaroxime Inhibition 12904068, 12388640, 17239702
HSD11B2 11 beta-Hydroxysteroid dehydrogenase Enoxolone Inhibition 8504732, 16012754, 16309197, 16391818, 17566745,
18721818, 18600055, 19949310, 24613819
H19 H19 BC-822 Inhibition
PDGF PDGF CR002 Inhibition 17308324, 16510766, 12937299




ACACA Acetyl-CoA carboxylase 1 isoform 1 CP-640186 Inhibition 12842871, 15341732, 23358327, 15934915
CP-610431 Inhibition 12842871
SRPK2 SRPK2 SRPIN340 Inhibition 16840555, PMC2916360
GBF1 GBF1 Brefeldin A Inhibition 3192548, PMC160661, 2004424
The CortellisTM drugs list has been compared and expanded using others public databases as described in Materials and Methods section.
induce the non-proteolytic disassembly of the spindle checkpoint
during mitosis (Jin et al., 2008; Manchado et al., 2010; Pawar
et al., 2010). For these reasons, Cdc27 functional product has
been identified as amolecular target of the curcumin-induced cell
cycle arrest and apoptosis in Shh-type MB (Lee and Langhans,
2012). The therapeutic properties of this natural substance were
already shown in Shh-driven MB models, highlighting its ability
to inhibit the Shh signaling, to reduce the level of β-catenin
and to inhibit HDAC4 (Elamin et al., 2010; Lee et al., 2011).
Thus, the up-regulation of Cdc27 after ablation of Tis21may be a
tumorigenic factor.
Of interest as drug target among the genes belonging to the
migration processes is Timp1. Its signal trasduction pathway
results in the migration of hNSCs, showing chemoattractant
properties and being identified in the same study as a therapeutic
target for human glioma (Lee et al., 2014). Here we suggest the
same prospective use of Timp1 in MB Shh-type.
The Cdc42bpb produces a Rho GTPase activated
serine/threonine kinase, which, by regulating the (non-
muscle) cytoskeletal actomyosin, influences cell shape and
promotes motility and migration (Tan et al., 2008, 2011), thus
acting also as a key regulator of tumor cell invasion. Cdc42bpb
is therefore an interesting drug target (Heikkila et al., 2011;
Unbekandt et al., 2014). It’s down-regulation in our Set A
data is in line with the GCPs migration failure, consistently
with the deregulation of others migration regulators discussed
above.
Genes involved in the RNA processing are Smg1 and Upf3b,
respectively down- and up-regulated in Set A. Interestingly, both
genes encode for proteins involved in alternative splicing (AS)
coupled with Nonsense-Mediated Decay (NMD) mechanism by
which NMD controls transcript abundance by regulating AS;
in fact, the SURF complex, which includes the SMG1–UPF1–
eRF1–eRF3 proteins, forms a bridge between the ribosome
and the downstream exon-junction complex (EJC) associated
with UPF3b and UPF2 (Chamieh et al., 2008; McIlwain et al.,
2010). Moreover, Smg1 has been showed to be involved in
the predisposition to tumor formation and inflammation in
Smg1 heterozygous mice; this mouse model presents elevated
basal tissue and serum cytokine levels—indicating low-level
inflammation—and can progress to chronic inflammation or
enhanced cancer development. Therefore, this is a model of
inflammation-enhanced cancer development (Roberts et al.,
2013), also suggesting that Smg1 is a tumor suppressor (Du et al.,
2014). To our knowledge, the possibility to target inflammation
through Smg1 has never been applied to medulloblastoma until
now. Furthermore, in our data Il1b, for example, is up-regulated
in Set D and B (See Figure 2); also Cxcl12 is up-regulated in
Set D, B, and also in Set A, as mentioned previously, while
Cxcl3 is down-regulated in Set A. It is also worth noting the
existence of an anticoagulant inhibitor of CXCL12/CXCR4 axis,
the Tinzaparin, as well as other heparinoids that have been
studied in brest cancer models for their heparinoid-mediated
inhibition of chemotaxis activity (Harvey et al., 2007; Mellor
et al., 2007). As Cxcl12 favors the localization of the GCPs to the
EGL by chemoattraction, an inhibitor of Cxcl12 might achieve
an opposite effect, similar to the promigratory effect exerted by
Cxcl3.
SUMMARY AND CONCLUSIONS
During cerebellar development, Shh is expressed in Purkinje
cells and regulates the proliferation of GCPs acting as mitogen
(Dahmane and Ruiz i Altaba, 1999; Wallace, 1999; Wechsler-
Reya and Scott, 1999). GPCs undergo a prolongedmitotic activity
in the EGL during the early postnatal period in the mouse. After
this intense proliferative phase, around the second postnatal week
in mouse, GPCs exit the cell cycle and migrate radially to the
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TABLE 4 | A list containing the indirect drug-target interactions obtained using MetaCoreTM.
MetaCoreTM Secondary Drug-target Interactions
Drug Gene Symbol Target Effect Pubmed







Midostaurin intracellular LATS2 LATS2 Unspecified 19654408
FRK FRK Unspecified 19654408
SRPK2 SRPK2 Unspecified 19654408
SIK2 QIK Unspecified 19654408
Ca(’2+) cytosol DGKB Diacylglycerol kinase, beta Activation 9003401, 16288460, 10206945, 12832407
PADI4 PAD4 Activation 11798170, 15247907
DGKA DGK-alpha Activation 9003401, 16288460, 10206945, 12832407
DGKG Diacylglycerol kinase, gamma Activation 9003401, 16288460, 10206945, 12832407
VDAC1 VDAC 1 Activation 12022949, 16597621
Estradiol extracellular region BTG2 BTG2 Inhibition 12959972
RGS5 RGS5 Inhibition 17374850
CXCL12 SDF-1 Activation 17362937, 17555868
HSD11B2 HSD11B2 Inhibition 9623596, 10503719
Dabrafenib intracellular FRK FRK Inhibition
TAOK2 TAO2 Inhibition
SIK2 QIK Inhibition
Vandetanib intracellular CDC42BPB CDC42BPB Unspecified 22037378
FRK FRK Unspecified 22037378
SIK2 QIK Inhibition 22037377, 22037378
Tozasertib intracellular TAOK2 TAO2 Unspecified 22037378
SRPK2 SRPK2 Unspecified 18183025,22037378
SIK2 QIK Unspecified 18183025,22037378
Retinoic acid extracellular region PADI4 PAD4 Activation 10488123
ADAMTS5 Aggrecanase-2 Activation 17255106
Uprosertib intracellular NLK NLK Inhibition
FRK FRK Inhibition
Dexamethasone extracellular region SLC25A15 SLC25A15 (ORC1) Activation 12055339, 11997094
HSD11B2 HSD11B2 Activation 16872738
Zn(’2+) nucleus ZNF286A ZNF286A Unspecified 11347906
BSN Bassoon Unspecified 9806829, 9679147, 9679147
Pazopanib extracellular region FRK FRK Unspecified 22037378
TAOK2 TAO2 Unspecified 22037378
Masitinib intracellular FRK FRK Inhibition 22037378
Pyridoxal Phosphate intracellular SLC25A15 SLC25A15 (ORC1) Inhibition 12807890
ACACA ACACA Inhibition 16249179
Fedratinib intracellular TAOK2 TAO2 Inhibition
SIK2 QIK Inhibition
Nilotinib intracellular CDC42BPB CDC42BPB Unspecified 22037378
FRK FRK Inhibition 22037378
Epigallocatechin-3-gallate extracellular region CXCL1 GRO-1 Inhibition
TAK-901 intracellular FRK FRK Inhibition
SIK2 QIK Inhibition
(Continued)
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TABLE 4 | Continued
MetaCoreTM Secondary Drug-target Interactions
Drug Gene Symbol Target Effect Pubmed
INK128 intracellular FRK FRK Inhibition
SIK2 QIK Inhibition
Ibrutinib intracellular FRK FRK Inhibition
Zn(’2+) extracellular region ADAMTS10 ADAM-TS10 Activation 11867212
ADAMTS5 Aggrecanase-2 Activation 11867212
TG100115 intracellular LATS2 LATS2 Unspecified
Perphenazine extracellular region ATP1A1 ATP1A1 Unspecified 6167716
Pamapimod intracellular NLK NLK Unspecified
Eprosartan extracellular region AGTR2 AGTR2 Inhibition 2016730, 8515425
Aclarubicin intracellular TIMP1 TIMP1 Activation 12118337
Promazine extracellular region ATP1A1 ATP1A1 Unspecified 6167716
Phenoxybenzamine extracellular region ATP1A1 ATP1A1 Inhibition 2576298
Carbenoxolone intracellular HSD11B2 HSD11B2 Inhibition 10566667, 10664531, 12190302
Anisindione intracellular ACACA ACACA Unspecified 4067989
Maprotiline extracellular region ATP1A1 ATP1A1 Inhibition 2576298
Irbesartan extracellular region AGTR2 AGTR2 Inhibition 2329553
Prazepine extracellular region ATP1A1 ATP1A1 Inhibition 2576298
lorcainide extracellular region ATP1A1 ATP1A1 Inhibition 10593659
Pirfenidone intracellular TIMP1 TIMP1 Inhibition 17086734
NO extracellular region SLC6A6 SLC6A6 Activation 11698241, 14992266, 15166008
Taurine extracellular region SLC6A6 SLC6A6 Inhibition 9130593, 10936171, 12437590
Fenoprofen intracellular ACACA ACACA Inhibition 1347398
Meloxicam extracellular region TIMP1 TIMP1 Inhibition 16536903
Promethazine extracellular region ATP1A1 ATP1A1 Unspecified 6167716
Biotin intracellular ACACA ACACA Activation 12421859, 14749229, 15539280
Furosemide intracellular HSD11B2 HSD11B2 Inhibition 9724039
Dimethyl sulfoxide intracellular PADI4 PAD4 Activation 10488123
Thiram intracellular HSD11B2 HSD11B2 Inhibition 12901862
Disopyramide extracellular region ATP1A1 ATP1A1 Inhibition 10593659
Fluoxymesterone intracellular HSD11B2 HSD11B2 Inhibition
Digitoxin extracellular region ATP1A1 ATP1A1 Inhibition 11525233
Methylene blue intracellular GUCY1A3 GUCY1A3 Inhibition 12031394, 12729841
Heparin extracellular region CXCL12 SDF-1 Inhibition 10570220, 15741341, 17264079, 17726466
Atenolol extracellular region ATP1A1 ATP1A1 Inhibition 11201505
Hg(’2+) extracellular region SLC25A15 SLC25A15 (ORC1) Inhibition 12807890
Procainamide extracellular region ATP1A1 ATP1A1 Inhibition 10593659
Trazodone extracellular region ATP1A1 ATP1A1 Inhibition 2576298
Nicotinic acid intracellular ACACA ACACA Inhibition 8857918, 10195935, 11171611, 12873710,
15030302
Imatinib intracellular FRK FRK Unspecified 15711537, 18183025, 22037378
Sotalol extracellular region ATP1A1 ATP1A1 Unspecified 11201505
Tocainide extracellular region ATP1A1 ATP1A1 Inhibition
TRV-120027 extracellular region AGTR2 AGTR2 Unspecified
Ruxolitinib intracellular TAOK2 TAO2 Unspecified 22037378
Ruboxistaurin intracellular LATS2 LATS2 Unspecified 22037378
Cisplatin extracellular region ATP1A1 ATP1A1 Inhibition
Trifluoperazine extracellular region ATP1A1 ATP1A1 Unspecified 6167716
Doxycycline intracellular TIMP1 TIMP1 Activation 20874665, 17122880, 17145119, 19442784
(Continued)
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TABLE 4 | Continued
MetaCoreTM Secondary Drug-target Interactions
Drug Gene Symbol Target Effect Pubmed
Losartan extracellular region AGTR2 AGTR2 Inhibition 1469703, 1875348, 1920360, 7473594,
7562905, 7606390, 7990105, 8064808,
8246245, 8277505, 8277506, 8340920,
8421274, 11310611, 11749394, 12213451,
16039125, 7990105, 14761190
Silmitasertib intracellular SRPK2 SRPK2 Inhibition
Chlorpromazine extracellular region ATP1A1 ATP1A1 Unspecified 6167716
R547 intracellular TAOK2 TAO2 Unspecified 22037378
17alpha-Hydroxyprogesterone extracellular region HSD11B2 HSD11B2 Inhibition 10566667
Alprazolam extracellular region ATP1A1 ATP1A1 Inhibition 2576298
Digoxin extracellular region ATP1A1 ATP1A1 Inhibition 11072868
CFI-400945 intracellular NLK NLK Unspecified
Clotiapine extracellular region ATP1A1 ATP1A1 Inhibition 2576298
Indenolol extracellular region ATP1A1 ATP1A1 Inhibition 1685314, 11201505
Testosterone extracellular region ACACA ACACA Activation 16579987
Aldosterone extracellular region ATP1A1 ATP1A1 Activation 16767692, 10718622
Encainide extracellular region ATP1A1 ATP1A1 Inhibition 2168576, 10593659
Regorafenib intracellular FRK FRK Inhibition
Cholic acid intracellular HSD11B2 HSD11B2 Inhibition 12015312
BMS-387032 intracellular TAOK2 TAO2 Unspecified
Angiotensin II extracellular region AGTR2 AGTR2 Activation 16570916, 2362273
Tivozanib intracellular FRK FRK Inhibition
Clofilium extracellular region ATP1A1 ATP1A1 Inhibition 15637453
Amoxapine extracellular region ATP1A1 ATP1A1 Inhibition 2576298
Tranilast intracellular TIMP1 TIMP1 Inhibition 16393468
Zn(’2+) cytosol RBM5 RBM5 Unspecified 10352938
Androstanolone extracellular region RPS12 RPS12 Inhibition 15525599
Ketoconazole intracellular HSD11B2 HSD11B2 Inhibition 10664531
Thioridazine extracellular region ATP1A1 ATP1A1 Unspecified 6167716
Retinoic acid intracellular GCNT3 GCNT3 Activation 15591039
Prochlorperazine extracellular region ATP1A1 ATP1A1 Unspecified 6167716
Latanoprost extracellular region TIMP1 TIMP1 Activation 12454040
Piperacillin intracellular LACTB LACTB Inhibition
Afatinib intracellular FRK FRK Inhibition
Afuresertib intracellular NLK NLK Inhibition
Topiramate intracellular ACACA ACACA Activation 16415917
Nebentan extracellular region AGTR2 AGTR2 Unspecified
Celiprolol intracellular ATP1A1 ATP1A1 Inhibition 1685314, 11201505
Disulfiram intracellular HSD11B2 HSD11B2 Inhibition 12901862
Cimetidine intracellular PADI4 PAD4 Unspecified
Candesartan extracellular region AGTR2 AGTR2 Unspecified 16039125
Progesterone intracellular HSD11B2 HSD11B2 Inhibition 9623596, 10566667, 10664531, 12915667,
9055382
Loxapine extracellular region ATP1A1 ATP1A1 Inhibition 2576298
Nadolol extracellular region ATP1A1 ATP1A1 Inhibition 11201505
Hydrochlorothiazide intracellular HSD11B2 HSD11B2 Inhibition 10334975
Deoxycholic acid intracellular HSD11B2 HSD11B2 Inhibition 12015312
Metoprolol extracellular region ATP1A1 ATP1A1 Inhibition 11201505
D-Glucose extracellular region SLC6A6 SLC6A6 Inhibition 10516137, 12870156
Paricalcitol PTH PTH Inhibition 9697664, 16797393
The only exception is the record related to the PTH gene that has been taken from Cortellis Drug Viewer list and compared with others public databases, as described in Materials and
Methods section.
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TABLE 5 | A drug-target interactions list and the correspondent source of information obtained using the Search Drug-Target Interactions tool on DGIdb,




Gene Drug Interaction Type Source Source Version
ACACA ACACA-acetyl-CoA carboxylase
alpha
TOFA n/a GuideToPharmacologyInteractions 04-mar-15
BIOTIN n/a DrugBank 3
ADAMTS5 ADAMTS5-ADAM
metallopeptidase with
thrombospondin type 1 motif, 5
n/a DrugBank 3
n/a DrugBank 3
BATIMASTAT n/a DrugBank 3
AGTR2 AGTR2-angiotensin II receptor,
type 2
PD123319 n/a GuideToPharmacologyInteractions 04-mar-15




CGP42112 n/a GuideToPharmacologyInteractions 04-mar-15
ANGIOTENSIN III n/a GuideToPharmacologyInteractions 04-mar-15
ANGIOTENSIN II n/a GuideToPharmacologyInteractions 04-mar-15
NOVOKININ n/a GuideToPharmacologyInteractions 04-mar-15
ANGIOTENSIN A n/a GuideToPharmacologyInteractions 04-mar-15
CANDESARTAN
CILEXETIL
Antagonist TTD 4.3.02 (2011.08.25)
TAK-491 Antagonist TTD 4.3.02 (2011.08.25)
PS433540 Antagonist TTD 4.3.02 (2011.08.25)
AZILSARTAN Antagonist TTD 4.3.02 (2011.08.25)
AZILSARTAN MEDOXOMIL Antagonist TTD 4.3.02 (2011.08.25)
TAK-591 Antagonist TTD 4.3.02 (2011.08.25)
TASOSARTAN Antagonist DrugBank 3
ATP1A1 ATP1A1-ATPase, Na/K
transporting, alpha 1 polypeptide
ALMITRINE n/a TEND 01-Aug-2011
BEPRIDIL n/a TEND 01-Aug-2011
ACETYLDIGITOXIN n/a TEND 01-Aug-2011
OUABAIN n/a TEND 01-Aug-2011
DIGOXIN n/a TEND 01-Aug-2011
DIGITOXIN n/a TEND 01-Aug-2011
DESLANOSIDE n/a TEND 01-Aug-2011
ACETYLDIGITOXIN n/a GuideToPharmacologyInteractions 04-mar-15
DESLANOSIDE n/a GuideToPharmacologyInteractions 04-mar-15
DIGITOXIN n/a GuideToPharmacologyInteractions 04-mar-15
DIGOXIN n/a GuideToPharmacologyInteractions 04-mar-15
OUABAIN Binder TTD 4.3.02 (2011.08.25)
LUMEFANTRINE Binder TTD 4.3.02 (2011.08.25)
CICLOPIROX Binder TTD 4.3.02 (2011.08.25)
ALUMINIUM Binder TTD 4.3.02 (2011.08.25)
CHLOROPROCAINE Blocker TTD 4.3.02 (2011.08.25)
ARTEMETHER Binder TTD 4.3.02 (2011.08.25)
ALMITRINE Binder TTD 4.3.02 (2011.08.25)
DESLANOSIDE Binder TTD 4.3.02 (2011.08.25)
DIGITOXIN Inhibitor DrugBank 3
HYDROFLUMETHIAZIDE Other/Unknown DrugBank 3
(Continued)
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Gene Drug Interaction Type Source Source Version
BEPRIDIL Inhibitor DrugBank 3
DIGOXIN n/a DrugBank 3
ACETYLDIGITOXIN Inhibitor DrugBank 3
ALUMINIUM Binder DrugBank 3
MAGNESIUM n/a DrugBank 3
ETHACRYNIC ACID Inhibitor DrugBank 3
DIAZOXIDE Other/Unknown DrugBank 3
TRICHLORMETHIAZIDE Inhibitor DrugBank 3
POTASSIUM n/a DrugBank 3
DESLANOSIDE Inhibitor DrugBank 3
ALMITRINE Binder DrugBank 3
OUABAIN Inhibitor DrugBank 3




ARCITUMOMAB Antibody TTD 4.3.02 (2011.08.25)
CXCL12 CXCL12-chemokine (C-X-C
motif) ligand 12
TINZAPARIN Binder DrugBank 3
DEPTOR DEPTOR - DEP domain
containing MTOR-interacting
protein
AZD8055 Inhibitor MyCancerGenome 13-mar-13
MLN0128 Inhibitor MyCancerGenome 13-mar-13
OSI-027 Inhibitor MyCancerGenome 13-mar-13
ERLOTINIB Antagonist DrugBank 3
FRK FRK-fyn-related kinase REGORAFENIB Inhibitor MyCancerGenomeClinicalTrial 30-Feburary-2014
HSD11B2 HSD11B2-hydroxysteroid
(11-beta) dehydrogenase 2
NADH n/a DrugBank 3







L-CITRULLINE n/a DrugBank 3
PDGFD PDGFD-platelet derived growth
factor D
SUNITINIB Inhibitor MyCancerGenomeClinicalTrial 30-Feburary-2014
PPP1R13L PPP1R13L-protein phosphatase
1, regulatory subunit 13 like
CISPLATIN n/a PharmGKB 12-Jul-2012
CYCLOPHOSPHAMIDE n/a PharmGKB 12-Jul-2012
THALIDOMIDE n/a PharmGKB 12-Jul-2012
PLATINUM COMPOUNDS n/a PharmGKB 12-Jul-2012
PLATINUM n/a PharmGKB 12-Jul-2012
PTH PTH-parathyroid hormone NORLEUCINE n/a DrugBank 3
SLC25A15 SLC25A15-solute carrier family
25 (mitochondrial carrier;
ornithine transporter) member 15
L-ORNITHINE n/a DrugBank 3
SRPK2 SRPK2-SRSF protein kinase 2 PHOSPHOAMINOPHOSPHONIC
ACID-ADENYLATE ESTER
n/a DrugBank 3
PURVALANOL n/a DrugBank 3




TAOK2 TAOK2-TAO kinase 2 PHOSPHONOSERINE n/a DrugBank 3
VDAC1 VDAC1-voltage-dependent
anion channel 1
DIHYDROXYALUMINIUM Inhibitor DrugBank 3
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TABLE 6 | A sub-list of Set A genes with the correspondent selected druggable gene category and source of information obtained using the Search
Druggable Gene Categories tool on DGIdb, where a druggable gene category is a group of genes that are thought to be potentially druggable by various
methods of prediction.
DGIdB Druggable Targets
Search term Gene Druggable Gene Category Sources
ACACA ACACA-acetyl-CoA carboxylase alpha DRUGGABLE GENOME HopkinsGroom RussLampel
DRUG RESISTANCE GO
ADAMTS10 ADAMTS10-ADAM metallopeptidase with
thrombospondin type 1 motif, 10
PROTEASE GO dGene
NEUTRAL ZINC METALLOPEPTIDASE GO
DRUGGABLE GENOME RussLampel dGene
ADAMTS5 ADAMTS5-ADAM metallopeptidase with
thrombospondin type 1 motif, 5
DRUGGABLE GENOME RussLampel dGene
PROTEASE GO dGene
NEUTRAL ZINC METALLOPEPTIDASE GO
AGTR2 AGTR2-angiotensin II receptor, type 2 G PROTEIN COUPLED RECEPTOR dGene GO HopkinsGroom
DRUGGABLE GENOME dGene RussLampel HopkinsGroom
AKAP2 AKAP2-A kinase (PRKA) anchor protein 2 KINASE GO





BTG2 BTG2-BTG family, member 2 DNA REPAIR GO
CDC27 CDC27-cell division cycle 27 homolog (S. cerevisiae) TUMOR SUPPRESSOR GO
CDC42BPB CDC42BPB-CDC42 binding protein kinase beta
(DMPK-like)
DRUGGABLE GENOME RussLampel dGene HopkinsGroom
SERINE THREONINE KINASE dGene GO
KINASE GO HopkinsGroom
CXCL1 CXCL1-chemokine (C-X-C motif) ligand 1 GROWTH FACTOR GO
CXCL12 CXCL12-chemokine (C-X-C motif) ligand 12 CELL SURFACE GO




DAZL DAZL-deleted in azoospermia-like TUMOR SUPPRESSOR GO
DEK DEK - DEK oncogene DNA REPAIR GO
DGKQ DGKQ-diacylglycerol kinase, theta 110 kDa KINASE GO
TRANSCRIPTION FACTOR BINDING GO
DPP10 DPP10-dipeptidyl-peptidase 10 (non-functional) DRUGGABLE GENOME RussLampel HopkinsGroom dGene
PROTEASE HopkinsGroom GO dGene
EFNA4 EFNA4-ephrin-A4 KINASE GO
TYROSINE KINASE GO
ERG ERG-v-ets erythroblastosis virus E26 oncogene homolog
(avian)
CLINICALLY ACTIONABLE FoundationOneGenes
FOXF2 FOXF2-forkhead box F2 TRANSCRIPTION FACTOR COMPLEX GO
TRANSCRIPTION FACTOR BINDING GO
FRK FRK-fyn-related kinase KINASE GO HopkinsGroom
TYROSINE KINASE GO dGene
DRUGGABLE GENOME HopkinsGroom dGene RussLampel
GPR82 GPR82-G protein-coupled receptor 82 G PROTEIN COUPLED RECEPTOR dGene GO HopkinsGroom
DRUGGABLE GENOME dGene RussLampel HopkinsGroom
GTPBP4 GTPBP4-GTP-binding protein 4 TUMOR SUPPRESSOR GO
GUCY1A3 GUCY1A3-guanylate cyclase 1, soluble, alpha 3 DRUGGABLE GENOME HopkinsGroom RussLampel
(Continued)
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TABLE 6 | Continued
DGIdB Druggable Targets
Search term Gene Druggable Gene Category Sources





IPO7 IPO7-importin 7 TRANSPORTER GO




LARS LARS-leucyl-tRNA synthetase DRUGGABLE GENOME HopkinsGroom RussLampel
LATS2 LATS2-LATS, large tumor suppressor, homolog 2
(Drosophila)
SERINE THREONINE KINASE GO dGene
KINASE GO HopkinsGroom
TUMOR SUPPRESSOR GO
DRUGGABLE GENOME HopkinsGroom dGene RussLampel
NAPEPLD NAPEPLD - N-acyl phosphatidylethanolamine
phospholipase D
PHOSPHOLIPASE GO
NLK NLK-nemo-like kinase KINASE HopkinsGroom GO
DRUGGABLE GENOME HopkinsGroom dGene RussLampel
SERINE THREONINE KINASE dGene GO
TRANSCRIPTION FACTOR BINDING GO
PA2G4 PA2G4-proliferation-associated 2G4, 38 kDa DRUGGABLE GENOME RussLampel HopkinsGroom
TUMOR SUPPRESSOR GO
PROTEASE HopkinsGroom
PAFAH1B1 PAFAH1B1-platelet-activating factor acetylhydrolase 1b,
regulatory subunit 1 (45 kDa)
TUMOR SUPPRESSOR GO
PDGFD PDGFD-platelet-derived growth factor D GROWTH FACTOR GO
PPP1R13L PPP1R13L-protein phosphatase 1, regulatory subunit 13
like
TRANSCRIPTION FACTOR BINDING GO
PTH PTH-parathyroid hormone HORMONE ACTIVITY GO
RBM5 RBM5-RNA binding motif protein 5 DRUGGABLE GENOME HopkinsGroom RussLampel
RIPK3 RIPK3-receptor-interacting serine-threonine kinase 3 DRUGGABLE GENOME RussLampel dGene
SERINE THREONINE KINASE GO dGene
KINASE GO
SENP7 SENP7-SUMO1/sentrin specific peptidase 7 PROTEASE dGene GO
DRUGGABLE GENOME dGene
SIK2 SIK2-salt-inducible kinase 2 SERINE THREONINE KINASE GO dGene
KINASE GO HopkinsGroom
DRUGGABLE GENOME RussLampel HopkinsGroom dGene
SLC25A15 SLC25A15-solute carrier family 25 (mitochondrial carrier;
ornithine transporter) member 15
TRANSPORTER GO
DRUGGABLE GENOME RussLampel
SLC6A6 SLC6A6-solute carrier family 6 (neurotransmitter
transporter, taurine), member 6
DRUGGABLE GENOME RussLampel HopkinsGroom
TRANSPORTER GO HopkinsGroom
SMG1 SMG1-smg-1 homolog, phosphatidylinositol
3-kinase-related kinase (C. elegans)
PHOSPHATIDYLINOSITOL 3 KINASE HopkinsGroom
DRUGGABLE GENOME HopkinsGroom RussLampel dGene
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TABLE 6 | Continued
DGIdB Druggable Targets
Search term Gene Druggable Gene Category Sources
SRPK2 SRPK2-SRSF protein kinase 2 SERINE THREONINE KINASE GO dGene
KINASE GO
TUMOR SUPPRESSOR GO
DRUGGABLE GENOME RussLampel dGene
SYT11 SYT11-synaptotagmin XI TRANSPORTER GO
TAF7 TAF7-TAF7 RNA polymerase II, TATA box binding protein
(TBP)-associated factor, 55 kDa
TRANSCRIPTION FACTOR COMPLEX GO
HISTONE MODIFICATION GO
TRANSCRIPTION FACTOR BINDING GO
TAOK2 TAOK2-TAO kinase 2 KINASE HopkinsGroom GO
DRUGGABLE GENOME HopkinsGroom RussLampel dGene
SERINE THREONINE KINASE dGene GO
TUMOR SUPPRESSOR GO
TIMP1 TIMP1-TIMP metallopeptidase inhibitor 1 PROTEASE INHIBITOR GO dGene
DRUGGABLE GENOME dGene
TOMM22 TOMM22-translocase of outer mitochondrial membrane
22 homolog (yeast)
TRANSPORTER GO
UPF3B UPF3B-UPF3 regulator of nonsense transcripts homolog
B (yeast)
TRANSPORTER GO
USP36 USP36-ubiquitin specific peptidase 36 PROTEASE dGene GO
DRUGGABLE GENOME dGene
VDAC1 VDAC1-voltage-dependent anion channel 1 TRANSPORTER GO
ION CHANNEL GO
ZC3H12D ZC3H12D-zinc finger CCCH-type containing 12D TUMOR SUPPRESSOR GO
IGL, along the Bergmann glia. During this inward migration,
differentiation of post-mitotic GPCs takes place, allowing the
mature granule neurons to expand the IGL, where they extend
dendrites (Dyer, 2004; Rodini et al., 2010; Wang and Wechsler-
Reya, 2014). As a consequence of a hyperactivation of the
Shh pathway occurring in the Ptch1+/− MB mouse model, the
prolonged mitotic activity of GCPs makes them potential targets
for transforming insults, leading to MB (Wang and Zoghbi,
2001).
Mutations in Ptch1 occur in sporadic humanMB and promote
the tumor in Ptch1 heterozygous mouse models at a rate of
approximately 8% within 12 weeks of age and up to 30% between
12 and 25 weeks of age (Goodrich et al., 1997). As previously
described (Farioli-Vecchioli et al., 2012a), the ablation of Tis21
in our mouse model strikingly enhances, from 25 to 80%, the
incidence of MB spontaneously occurring in Ptch1 heterozygous
mice. We observe that the whole balance between division,
differentiation and death is disrupted in Ptch1 heterozygous
GCPs lacking Tis21, leading to an increase in tumor incidence
(Farioli-Vecchioli et al., 2012a). In particular, Tis21 seems to act
on the timing of migration of GPCs from EGL to IGL, causing
an extended period of localization in the proliferative region,
decrease of differentiation and increase of apoptosis (Farioli-
Vecchioli et al., 2012a,b). These cellular changes are mirrored in
gene expression changes occurring in Set A, shown in Table 1.
We observe that the most significant enrichments of genes whose
expression is altered in Set A, fall in the functional pathways
of developmental signaling, retinal development, cell migration,
epigenetic modulation, and primary cilium-related activities. We
will summarize some consideration on these functions and also
about the ubiquitin-dependent degradation (Table 1), in relation
to the possible drug targets available.
Cell Cycle Regulation and Cell Proliferation
of the GCPs (Set A)
We have shown that no change in the proliferation of GCPs
occurs after ablation of Tis21 (Farioli-Vecchioli et al., 2012a).
Moreover, in a recent study, we have demonstrated that the
proliferation of the GCPs is not ruled by Tis21 but by the
family-related gene Btg1 (Ceccarelli et al., 2015). Indeed, if we
analyze the type of expression changes occurring in the whole
array of genes of Set A that either directly or indirectly regulate
the proliferation and/or the cell cycle of the GCPs (Table 7)
we find that there is upregulation as well downregulation of
genes that affect either positively or negatively this process,
evidently resulting in no net change of proliferation of the GCPs.
Nonetheless, the defect of migration of the Tis21-null GCPs
forces them to stay a longer period in the EGL under the control
of Shh influence, possibly leading to different types of alterations
in cell division, including the control of centrosome assembly (see
below).
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TABLE 7 | The table shows a sub-set of Set A deregulated genes which
can influence proliferation in a direct or indirect manner.
Genes Functional Expression Effect on Oncosuppressor
classes level proliferation gene
Gtpbp4 Proliferation Up +
Ipo7 Cell Cycle Up +
Eif3a Cell Cycle Up +
Eif3c Cell Cycle Up +
Cdc27 Cell Cycle Up +
Ckap5 Cell Cycle Up +
Ankrd11 Epigenetic Up +
Mphosph10 Cell Cycle Up +
Rps12 Proliferation Up +
Rrp1 Cell Cycle Up +
Srpk2 Cell Cycle Up +
Taf7 Cell Cycle Up +
Taok2 Cell Cycle Up +
Slc6a6 Proliferation Up +
Agtr2 Proliferation Up −




Pag1 Proliferation Down − X
Rab11fip4 Cell Cycle Down −
Lats2 Cell Cycle Down − X
Tigar
(9630033F20Rik)




Zc3h12d Cell Cycle Down − X
Gcnt3 Proliferation Down +
Sik2 Cell Cycle Down +
Wtap Cell Cycle Down +
Cilium, GCPs Migration, Clathrin Motility,
and Centrosome Assembly (Set A)
We have shown a link between the Shh signaling, operating
through the primary cilium, and the impairment of cell
migration, i.e., the main phenotype observed in Ptch+/−/Tis21KO
mice [17]. In fact, the primary cilium, as mentioned above, is
a sensory non-motile microtubule-based organelle which acts
as a subcellular compartment for Shh signaling through a
Smoothened-dependent recruitment of Gi proteins (Belgacem
and Borodinsky, 2011). These include the Rab11 family, which
impacts on cell motility, and whose components Fip4 and
Fip2 are down-regulated in Set A. Remarkably, Rab11Fip2
interacts with the myosin Vb motor protein (Horgan and
McCaffrey, 2009) that regulates the recycling of C-X-C
chemokine receptor type 2, the receptor of Cxcl3, and the
receptor-mediated chemotaxis, as confirmed by Raman et al.
(2014). As we have pointed out previously, Cxcl3 induces
the migration of GCPs out of the EGL and its decrease
in Set A is at the origin of the increase of tumorigenesis
in Tis21 KO model (Farioli-Vecchioli et al., 2012a). All this
points to a link between the decrease of the Cxcl3-Cxcr2
function in Set A and the clathrin-mediated chemotaxis and
microtubule-based migration. Such type of reasoning could be
extended to the whole set of coiled coil molecules present
in the cilium whose expression is altered in Set A, further
suggesting that the ablation of Tis21 in Set A could trigger
an impairment of GCPs migration acting at more than one
level.
Another interesting connection is with the cilium-based
GTPase Rab11Fip4; in fact, since Rab11Fip4 induces Gli3 (Muto
et al., 2007) which is a negative regulator of Shh signaling, the
ablation of Tis21, by down-regulating Rab11fip4, may enhance
the Shh pathway activity, thus conferring more penetrance to the
Shh stimulus. Moreover, the presence of cilia is in itself necessary
for the development of Shh-type MB, and the formation of
cilia might be enhanced by the upregulation in Set A of Syne2
(Chizhikov et al., 2007).
We also noticed several deregulated genes in Set A
related to an evident deregulation of centrosome assembly
(Akap2, Syne2, Ckap5, Sik2, Emd, and Lats2). Since the
basal bodies, microtubule-based structures, are required
for the formation of cilia (also non-motile ones) but
also for the pericentriolar material at the core of the
centrosome (Nigg and Raff, 2009), our results could confirm
the previously reported evidences of a deregulation of
centrosome and cilia biogenesis that have been described
in different types of cancer, where a derangement of cell cycle
checkpoints is governed by cilia and centrosomes (Plotnikova
et al., 2008; Nigg and Raff, 2009; Bettencourt-Dias et al.,
2011).
Primary Cilium (Set B)
In reference to set B (comparison of Ptch1 heterozygous mice
vs. wild-type, thus without involvement of Tis21) our attention
was captured by mechanisms that could regulate cell cycle
machinery in a primary cilia-dependent fashion. These are
suggestive of a possible involvement of Smo-dependent non-
canonical Shh-pathways, namely concerning our data showing
for the first time that Plc-gamma2, Ip3r3, Trpc1, Trpc2, and
Trpc3 are up-regulated in Ptch1 heterozygous mice. These
genes belong to the described Smo-dependent non-canonical
Shh pathways (Figure 3) that have been reported to modulate
cytoskeleton-dependent processes (Jenkins, 2009) and Ca2+
spikes (Brennan et al., 2012). In particular, a model in which the
subcellular compartment (i.e., primary cilium) for Shh signaling
allows the spatiotemporal integration of second messengers
has been proposed (Belgacem and Borodinsky, 2011), and
the role of Ca2+ signaling in granule cell turning and in
modulation of their migration rate has been suggested as
potential therapeutic target for some deficits in granule cell
migration, since its downstream effectors control the assembly
and disassembly of cytoskeletal elements (Komuro et al.,
2015).
The presence of the key components of the Shh pathway
in cilia has been assessed, as well as the anterograde and
retrograde traffic regulating its signaling (Goetz and Anderson,
2010). We have taken in consideration the role of primary
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cilia in GCPs, where their presence has been assessed in
the EGL at early post-natal stages (Del Cerro and Snider,
1972), as well as their requirement for Shh-induced expansion
and cerebellar development (Chizhikov et al., 2007; Spassky
et al., 2008). Exploring this scenario, in our MB mouse
model we have highlighted some other cilia-related protein
targets modified in Set B—but not in Set A—such as Tctex-1,
identified as a novel “checkpoint” for G1-S transition controlling
ciliary resorption, cell cycle S-phase entry and fate of neural
progenitors of developing neocortex (Li et al., 2011; Sung and Li,
2011).
Possible Lineage Switch of pGCPs in Set A
and Retinal Development
An intriguing observation concerns the fact that three genes in
Set A whose expression is significantly modified - namely, Nlk,
Raf1, and Ppp2r2b—are markers for group 3 medulloblastoma
(Kool et al., 2008; Gibson et al., 2010; Northcott et al., 2011,
2012c; Taylor et al., 2012; Hooper et al., 2014). Moreover, Nlk is
among the genes of Set A modified in retinal development, and
it has been suggested that cerebellar and retinal progenitor cells
have common evolutionary origin [76]. It is also worth noting
that, according to references (Kool et al., 2008; Hooper et al.,
2014), among the markers for group 3 MB there are many genes
involved in retinal development; in our Set A many genes as well
are involved in this process, Nlk being common. Additionally, in
Set A there are at least two genes whose expression is modified,
Gli1 and Pdgfd, which are markers of Shh-type medulloblastoma
(Kool et al., 2008; Gibson et al., 2010; Northcott et al., 2011,
2012c; Taylor et al., 2012; Hooper et al., 2014). Hence, the ablation
of Tis21 causes changes in the Ptch1 heterozygous Shh-type
model of two Shh-type MB marker genes (increased expression)
and of three group 3 MB marker genes (Table 1). As a whole,
these data may suggest the possibility that the ablation of Tis21,
by altering the expression of important Shh marker genes such
Pdgfd and Gli1, may increase the penetrance of the Shh-type
tumor phenotype, but also the possibility of a shift of the Shh
phenotype toward the group 3MB. A possible shift toward group
3, associated with retinal development control, may underlie
the intriguing novel concept that the inactivation of a gene—in
this case Tis21, which is known to be required for the terminal
differentiation of neural stem cells (Micheli et al., 2015)—may
favor in Shh-activated GCPs a lineage shift toward other neural
cell types involved in group 3 MB onset. Further analyses will be
necessary to clarify this possibility.
A further correlation concerns the up-regulation of Deptor
in Set A: this gene has been remarkably associated with
reduced differentiation and increase of regenerative potential
of pluripotent stem cells (Agrawal et al., 2014). Deptor
functional product also inhibits the TOR pathway, whose
activation results in a more penetrant phenotype in Shh-type
MB, with enhanced survival of cancer stem cells (Beauchamp
and Platanias, 2013). Thus, we can further suppose that the
ablation of Tis21 enhances the stem cell character of the
Shh–activated GCPs as a preliminary step to possible lineage
shifts.
Epigenetic Changes in GCPs of Set A
The most significant enrichment in Set A is probably observed
for genes that regulate transcription epigenetically. We have
previously performed a functional genomic analysis where we
identified more than 30 genes altered by the Tis21 KO genotype
relative to Tis21 wild-type, (in background either Ptch1 wild-
type or heterozygous) and involved in epigenetic control, being
regulated by DNAmethylation or histone deacetylation, or being
able to associate with HDAC1 or HDAC4 (Farioli-Vecchioli
et al., 2012b). We limited the present analysis within Set A
to genes acting as histone modifier and their regulators or
involved in chromatin remodeling, finding several of the first
class and one of the second. Among them, is relevant PadI4,
which by demethylating histones may act as a tumor suppressor
(Tanikawa et al., 2012); thus, its down-regulation in Set A
could enhance tumorigenesis. Remarkable is also the series of
histone modification editors ANKRDs, whose genes are down-
regulated in SetA. Among the chromatin modifiers, we find
Dek, up-regulated in Set A and also up-regulated in group
4 MB (Hooper et al., 2014), which is a known oncogene
that can confer stem cell-like qualities and is thus potentially
enhancing the probability of cancer (Privette Vinnedge et al.,
2013). Altogether, the alteration in Set A of genes involved in
histone modification and chromatin remodeling fits with the idea
that the ablation of Tis21 may reduce in the Tis21-null GCPs
the restraint toward a lineage shift, as exposed in the previous
section.
RNA Processing in Set A
The role of Tis21 in the cell proliferation control has been
recently associated in human cells to RNA deadenylation, by
which it influences mRNA poly(A) tail shortening (Stupfler
et al., 2016). Nevertheless, in Set A we detect the deregulation
of genes related to AS or to NMD, but not to mRNA
deadenylation.
Drug Targets
This is a very interesting topic for therapy, that will need
preclinical experimental studies for evaluation. Among
the Set A genes that could be targeted by a drug, are
worth mentioning: (i) the inhibitor of Pdgfd (ligand for
Pdgfrb), since the activation of the PDGFR pathway
has been shown to activate the Cxcl12 receptor; (ii) the
possibility to enhance the activity of the tumor suppressor
phosphatidylinositol 3-kinase-related kinase Smg1, whose
ablation favors inflammation and cancer development. This
could also be obtained by negatively targeting mTOR, which
is antagonistic to Smg1 (possibly also by enhancing Deptor
activity, which negatively regulates mTOR signaling). Moreover,
as mentioned above, the intracerebellar administration of Cxcl3
functional product, by controlling the timing of migration
of pre-neoplastic pGCPS, may have therapeutic effects that
still need to be fully tested in vivo. Since these genes are
deregulated in a Shh-type MB whose frequency is enhanced
by Tis21 ablation, and since Tis21 has been shown to be
down-regulated in human MBs (mainly Shh-type), it is
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plausible a benefit using Cxcl3 in MB therapy of at least the
Shh-type.
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